title: A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
abstract: Postherpetic neuralgia (PHN) is a painful complication of acute herpes zoster. This multicenter, double-blind, controlled study randomized 299 PHN patients to receive either NGX-4010, a high-concentration capsaicin (8%) patch, or a low-concentration capsaicin (0.04%) control patch for 30, 60, or 90 minutes. The mean percent reductions in NPRS score from baseline to weeks 2 through 8 were significantly greater in the total NGX-4010 group (26.5%, P = .0286) and the 90-minute NGX-4010 group (27.8%, P = .0438) compared to the pooled control group (17.3%). After review of the data suggested a difference between genders in reporting of pain scores and a higher proportion of males (61%) in the 60-minute NGX-4010 group, post hoc gender-stratified analyses were performed and showed that the 60-minute NGX-4010 group also had a significantly larger mean percent reduction in average pain scores (28.0%, P = .0331). Pain reduction in the 30-minute NGX-4010 group, although similar in magnitude to the other doses, was not significantly different from control in either of these analyses. Similar results were observed during weeks 2 through 12. Most treatment-emergent adverse events were application-site specific, transient and mostly mild to moderate in severity.
  
  
  CONCLUSIONS
  This article reports the safety and efficacy of NGX-4010 applied for 3 different durations (30, 60, or 90 minutes) in patients with PHN. The results identified the 60-minute duration as the dose to be evaluated in subsequent studies and identified a gender effect on reported changes in pain.
authors.affiliation: Lifetree Clinical Research and Pain Clinic, Salt Lake City, Utah 84106, USA. lynnw@lifetreeresearch.com
authors.forename: Lynn R
authors.initials: LR
authors.lastname: Webster
authors.forename: T Philip
authors.initials: TP
authors.lastname: Malan
authors.forename: Michael M
authors.initials: MM
authors.lastname: Tuchman
authors.forename: Martin D
authors.initials: MD
authors.lastname: Mollen
authors.forename: Jeffrey K
authors.initials: JK
authors.lastname: Tobias
authors.forename: Geertrui F
authors.initials: GF
authors.lastname: Vanhove
mesh_terms: D000279:Administration, Cutaneous; D000368:Aged; D000369:Aged, 80 and over; D000700:Analgesics / Q000008:administration & dosage* / Q000009:adverse effects; D000982:Antipruritics / Q000008:administration & dosage* / Q000009:adverse effects; D002211:Capsaicin / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D051474:Neuralgia, Postherpetic / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000700:Analgesics; D000982:Antipruritics; D002211:Capsaicin